Latest news with #BeiGene
Globe and Mail
07-08-2025
- Business
- Globe and Mail
Chronic Lymphocytic Leukemia Pipeline Outlook Report 2025: Key 55+ Companies and Breakthrough Therapies Shaping the Future Landscape
DelveInsight's, 'Chronic Lymphocytic Leukemia Pipeline Insight 2025' report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Chronic Lymphocytic Leukemia (CLL) pipeline landscape. It covers the Chronic Lymphocytic Leukemia pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Lymphocytic Leukemia pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Stay ahead with the latest insights! Download DelveInsight's comprehensive Chronic Lymphocytic Leukemia Pipeline Report to explore emerging therapies, key players, and future treatment landscapes @ Chronic Lymphocytic Leukemia Pipeline Outlook Report In July 2025, AstraZeneca announced a Phase IV study to evaluate the safety and tolerability of acalabrutinib (monotherapy, 100 mg orally [po], twice daily [bd]) compared to investigator's choice of treatment, in patients with CLL (TN or R/R) and moderate to severe cardiac impairment. All patients will have cardiac impairment as defined by LVEF of < 50%. In July 2025, BeiGene announced a study is to support the registration plan of sonrotoclax plus zanubrutinib treatment in participants with previously untreated CLL. This study is designed to assess the contribution of sonrotoclax to the efficacy outcome of the combination of zanubrutinib and sonrotoclax. In July 2025, AbbVie conducted a study doctors put the participants in 1 of 4 groups, called treatment arms. Participants will receive oral venetoclax in combination with intravenously (IV) infused obinutuzumab or oral acalabrutinib at in different dosing schemes as part of treatment. Approximately 120 adult participants with CLL who are being treated with venetoclax will be enrolled in the study in approximately 80 sites worldwide. DelveInsight's Chronic Lymphocytic Leukemia pipeline report depicts a robust space with 55+ active players working to develop 60+ pipeline therapies for Chronic Lymphocytic Leukemia treatment. The leading Chronic Lymphocytic Leukemia Companies such as Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Promising Chronic Lymphocytic Leukemia Therapies such as Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Discover how the Chronic Lymphocytic Leukemia treatment paradigm is evolving. Access DelveInsight's in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Chronic Lymphocytic Leukemia Clinical Trials and Studies Chronic Lymphocytic Leukemia Emerging Drugs Profile Pirtobrutinib: Loxo Oncology Pirtobrutinib is an investigational, oral, highly-selective, non-covalent Bruton's tyrosine kinase (BTK) inhibitor. BTK plays a key role in the B-cell antigen receptor, signaling pathway, which is required for the development, activation and survival of normal white blood cells, known as B-cells, and malignant B-cells. Pirtobrutinib was designed to reversibly bind BTK, deliver consistently high target coverage regardless of BTK turnover rate, preserve activity in the presence of the C481 acquired resistance mutations, and avoid off-target kinases that have complicated the development of both covalent and investigational non-covalent BTK inhibitors. The drug is currently being evaluated in Phase III stage of development for the treatment of chronic lymphocytic leukemia. Cirmtuzumab: Oncternal Therapeutics Cirmtuzumab is a first-in-class humanized monoclonal antibody that binds with high affinity to a biologically important epitope on ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1). ROR1 is a type 1 transmembrane protein, essential for fetal development that is expressed on the plasma membrane with an extracellular domain that is essential for ligand binding and signal transduction. Cirmtuzumab binds to many different types of cancer cells but does not recognize most normal adult tissues. Cirmtuzumab was developed at the University of California in San Diego based on the pioneering scientific research of Thomas Kipps, MD, Ph.D., and his colleagues at the Moores Cancer Center. Oncternal holds an exclusive worldwide license to develop and commercialize antibodies recognizing ROR1. The development of cirmtuzumab has been supported by the California Institute for Regenerative Medicine (CIRM), in recognition of the role of ROR1 in conferring stem cell-like properties to the cancer cells that express it. A Phase II clinical trial is evaluating Cirmtuzumab to treat CLL. MS-553: MingSight Pharmaceuticals MS-553 is a potent, highly selective, oral, non-covalent inhibitor of PKCβ, a signaling molecule immediately downstream of BTK and PLCγ2 in the B-cell receptor (BCR) pathway. As PKCβ is downstream of both BTK and PLCγ2, it has the potential to treat acquired BTK resistance mutations in either protein, a feature absent from many second-generation BTK inhibitors. In the preliminary results, MS-553 was generally well tolerated, with initial anti-tumor activity seen in the heavily pretreated population. Potent to full inhibition of PKCβ signaling over 24 hours of exposure has been demonstrated. Additional dosing of patients will be completed to further assess MS-553 efficacy in patients with acquired resistance mutations in BTK and PLCG2. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of CLL. NX-2127: Nurix Therapeutics NX-2127 is an oral small molecule that combines the activity of a targeted BTK degrader with the cereblon immunomodulatory activity of an IKZF degrader. Cereblon immunomodulatory drugs that induce degradation are IKZF1 and IKZF3. Preclinical data support the activity of NX-2127 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to FDA-approved agents. Studies in non-human primates confirm potent BTK degradation with once-daily oral dosing. NX-2127 is being tested in an ongoing Phase I trial for patients with chronic lymphocytic leukemia who have failed prior treatments. NX-5948: Nurix Therapeutics NX-5948 is an oral small molecule degrader of BTK. Preclinical data support the activity of NX-5948 in tumor models harboring either wild-type BTK or BTK with mutations conferring clinical resistance to leading FDA approved agents. NX-5948 lacks cereblon immunomodulatory activity and has demonstrated the ability to cross the blood-brain barrier in animal models. NX-5948 has also demonstrated activity in animal models of autoimmune disease. The drug is currently being evaluated in the Phase I stage of development for the treatment of chronic lymphocytic leukemia. The Chronic Lymphocytic Leukemia Pipeline Report Provides Insights into The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Lymphocytic Leukemia with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Lymphocytic Leukemia Treatment. Chronic Lymphocytic Leukemia Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Chronic Lymphocytic Leukemia Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Lymphocytic Leukemia market Explore groundbreaking therapies and clinical trials in the Chronic Lymphocytic Leukemia Pipeline. Access DelveInsight's detailed report now! @ New Chronic Lymphocytic Leukemia Drugs Chronic Lymphocytic Leukemia Companies Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic lymphocytic leukemia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Chronic Lymphocytic Leukemia Products have been categorized under various Molecule types such as Monoclonal antibody Small molecule Peptide Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Chronic Lymphocytic Leukemia Market Drivers and Barriers, and Future Perspectives Scope of the Chronic Lymphocytic Leukemia Pipeline Report Coverage- Global Chronic Lymphocytic Leukemia Companies- Loxo Oncology, Oncternal Therapeutics, MingSight Pharmaceuticals, Nurix Therapeutics, Starton Therapeutics, TG Therapeutics, Bristol Myers Squibb, Novartis, Aprea Therapeutics, AstraZeneca, Genor Biopharma, Incyte Corporation, MorphoSys, Astex Therapeutics, Lava Therapeutics, Celgene Corporation, and others. Chronic Lymphocytic Leukemia Therapies- Obinutuzumab, Rituximab, Chlorambucil, Acalabrutinib, and others. Chronic Lymphocytic Leukemia Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Chronic Lymphocytic Leukemia Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Which companies are leading the race in Chronic Lymphocytic Leukemia drug development? Find out in DelveInsight's exclusive Pipeline Report—access it now! @ Chronic Lymphocytic Leukemia Emerging Drugs and Major Companies Table of Contents Introduction Executive Summary Chronic lymphocytic leukemia: Overview Pipeline Therapeutics Therapeutic Assessment Chronic lymphocytic leukemia– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Pirtobrutinib: Loxo Oncology Drug profiles in the detailed report….. Mid Stage Products (Phase II) Cirmtuzumab: Oncternal Therapeutics Drug profiles in the detailed report….. Early Stage Products (Phase I) NX-2127: Nurix Therapeutics Drug profiles in the detailed report….. Preclinical and Discovery Stage Products Drug name: Company name Drug profiles in the detailed report….. Inactive Products Chronic lymphocytic leukemia Key Companies Chronic lymphocytic leukemia Key Products Chronic lymphocytic leukemia- Unmet Needs Chronic lymphocytic leukemia- Market Drivers and Barriers Chronic lymphocytic leukemia- Future Perspectives and Conclusion Chronic lymphocytic leukemia Analyst Views Chronic lymphocytic leukemia Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
27-07-2025
- Business
- Yahoo
BeOne Medicines Ltd. (ONC) Wins EU Nod for Tevimbra
We recently compiled a list of BeOne Medicines Ltd. stands ninth on our list. BeOne Medicines Ltd. (NASDAQ:ONC), formerly BeiGene, is a global oncology company now headquartered in Switzerland following its May 2025 redomiciliation. The strategic move enhances the company's access to European biotech networks and regulatory alignment, supporting its mission to lead in cancer innovation. With operations in over 45 countries and a pipeline of 50+ investigational assets, the business is rapidly expanding its R&D and clinical presence. A major milestone for BeOne Medicines Ltd. (NASDAQ:ONC) this year was the European Commission's approval of Tevimbra (tislelizumab) for multiple indications, including extensive-stage small cell lung cancer and nasopharyngeal carcinoma, further cementing its role in immuno-oncology. Tevimbra is already FDA-approved for esophageal cancer, and continued regulatory momentum is expected. In hematology, the corporation showcased significant advances at the 2025 EHA Congress. Sonrotoclax (a BCL2 inhibitor) and BGB-16673 (a first-in-class BTK degrader) delivered promising results in treating resistant forms of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), advancing toward Phase 3 trials. Meanwhile, BRUKINSA (zanubrutinib) remains a core therapy, demonstrating superior outcomes compared to ibrutinib. A pharmacy worker distributing prescription medicines to patientsreceiving treatment for oncology, cardiovascular, renal, metabolism and respiratory diseases. BeOne Medicines Ltd. (NASDAQ:ONC) also made strides in pipeline growth, advancing 13 new molecules into clinical trials in 2024 alone. With 170+ global trials and over 25,000 patients enrolled, its 'Fast to Proof-of-Concept' strategy accelerates timelines and patient access. In June 2025, a licensing deal with Neowise Biotechnology expanded the business's efforts in next-gen cell therapies, particularly TCR-based platforms.\ While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
15-07-2025
- Business
- Globe and Mail
Follicular Lymphoma Market Forecast 2034: EMA, PDMA, FDA Approval, Clinical Trials, Medication, Revenue, Statistics, Prevalence and Companies by DelveInsight
Follicular Lymphoma Market Growth Accelerates at a CAGR of 6% During the Forecast Period (2025-2034). Increased awareness of the disease has led to a higher number of treated cases, contributing to market growth. The rising number of clinical trials focused on follicular lymphoma are a significant driver of its market's expansion. Follicular Lymphoma Companies are Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, Abbvie, Novartis, Innovent Biologics, Regeneron, Genentech, Eli Lilly, more. (Albany, USA) DelveInsight's " Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast-2034 ' report offers an in-depth understanding of the Follicular Lymphoma, historical and forecasted epidemiology as well as the Follicular Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The Follicular Lymphoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Follicular Lymphoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Follicular Lymphoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Follicular Lymphoma market. Key highlights of the Follicular Lymphoma Market Report: The Follicular Lymphoma market size was valued ~USD 1,082 million in 2024 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In February 2025, Regeneron Pharmaceuticals announced the resubmission of the Biologics License Application (BLA) for odronextamab in relapsed/refractory follicular lymphoma to the FDA. The company expects a decision from the FDA in the second half of 2025. In February 2025, Genmab A/S (Nasdaq: GMAB) announced that the Japan Ministry of Health, Labour, and Welfare has approved EPKINLY Registered (epcoritamab) for treating patients with relapsed or refractory follicular lymphoma (FL; Grades 1 to 3A) who have undergone two or more prior treatments. This approval makes EPKINLY the first and only subcutaneously administered T-cell engaging bispecific antibody approved in Japan for both relapsed or refractory FL and large B-cell lymphomas, including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma, after two or more prior therapies. In January 2025, CRISPR Therapeutics announced plans to collaborate with regulatory authorities to determine the next steps for CTX112 in B-cell malignancies, with an update anticipated by mid-2025. In September 2024, The FDA granted Priority Review status to the Biologics License Application (BLA) for odronextamab, intended for the treatment of adults with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL) who have not responded to at least two prior systemic therapies. In 2024, approximately 35,000 cases of follicular lymphoma were diagnosed across the 7MM. In 2024, the United States generated around USD 1,082 million in revenue. In 2024, Germany represented the largest market size among the EU4 and the UK, with an estimated value of around USD 108 million. In 2024, Spain had the smallest market size among the EU4 and the UK, with an estimated value of around USD 61 million. In 2024, the United States had the highest number of Follicular Lymphoma cases among the 7MM, with approximately 17,000 cases. This number is expected to rise by 2034. In 2024, the 60-80 age group had the highest incidence of follicular lymphoma, with around 9,000 cases, followed by the 40-59 age group with approximately 4,000 cases. In 2024, stage IV follicular lymphoma cases accounted for approximately 34% of all cases. In 2024, the incidence of follicular lymphoma in the EU4 and the UK was approximately 14,000, with Germany reporting the highest number of cases. Key Follicular Lymphoma Companies: Roche, BeiGene, Kite Pharma, Incyte Corporation, AstraZeneca, Xynomic Pharmaceuticals, MEI Pharma, Novartis, Innovent Biologics, Regeneron, Genentech, Xynomic Pharma, Eli Lilly and Company, ADC Therapeutics S.A, BeiGene, Cephalon, Epizyme, Inc., Pharmacyclics LLC., Gemin X, AbbVie, Millennium Pharma, and others Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others The Follicular Lymphoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Follicular Lymphoma pipeline products will significantly revolutionize the Follicular Lymphoma market dynamics. Follicular Lymphoma Overview Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma that arises from B-lymphocytes, a type of white blood cell essential for the immune system. Follicular Lymphoma typically originates in the lymph nodes but can also affect the bone marrow and spleen. This form of lymphoma is characterized by the formation of abnormal follicles within lymph nodes, leading to painless swelling, fatigue, night sweats, and unexplained weight loss. Follicular Lymphoma most commonly affects adults over the age of 60 and is usually diagnosed through a combination of physical examination, blood tests, imaging studies, and biopsy. Genetic testing may also be used to identify specific mutations, such as the BCL2 gene rearrangement, which is often associated with this disease. Follicular Lymphoma treatment options vary depending on the stage and symptoms, ranging from active surveillance in early stages to targeted therapies, immunotherapy, chemotherapy, and radiation therapy in more advanced or symptomatic cases. While Follicular Lymphoma is generally considered incurable, it is highly treatable, and many patients live for years with proper disease management. Follicular Lymphoma research continues to advance, with clinical trials exploring novel therapies aimed at improving outcomes and extending progression-free survival, making the future more hopeful for affected patients. Follicular Lymphoma Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Follicular Lymphoma Epidemiology Segmentation: The Follicular Lymphoma market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into: Total Prevalence of Follicular Lymphoma Prevalent Cases of Follicular Lymphoma by severity Gender-specific Prevalence of Follicular Lymphoma Diagnosed Cases of Episodic and Chronic Follicular Lymphoma Download the report to understand which factors are driving Follicular Lymphoma epidemiology trends @ The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Follicular Lymphoma market or expected to get launched during the study period. The analysis covers Follicular Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Follicular Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Follicular Lymphoma Therapies and Key Companies LUNSUMIO (mosunetuzumab): Roche BRUKINSA (zanubrutinib): BeiGene YESCARTA: Kite Pharma MONJUVI (tafasitamab): Incyte Corporation AZD0486: AstraZeneca Abexinostat: Xynomic Pharmaceuticals ME-401: MEI Pharma Tisagenlecleucel: Novartis Parsaclisib (IBI376): Innovent Biologics Odronextamab: Regeneron Mosunetuzumab: Genetech Abexinostat: Xynomic Pharma Rituximab IV: Roche Atezolizumab (MPDL3280A) [TECENTRIQ]: Hoffmann-La Roche Enzastaurin: Eli Lilly and Company Loncastuximab tesirine: ADC Therapeutics S.A Zanubrutinib: BeiGene Bendamustine: Cephalon Tazemetostat: Epizyme, Inc. ibrutinib: Pharmacyclics LLC. Obatoclax mesylate: Gemin X Ibrutinib: AbbVie IXAZOMIB: Millennium Pharma To know more about Follicular Lymphoma companies working in the treatment market, visit @ Follicular Lymphoma Medication, Manufacturers and Therapeutic Assessment Follicular Lymphoma Market Outlook DelveInsight estimates that the US market size for follicular lymphoma is expected to grow from USD 1 billion in 2024 at a significant CAGR by 2034. The follicular lymphoma market is experiencing steady growth, driven by rising incidence rates, increasing awareness, and advancements in targeted therapies such as monoclonal antibodies and CAR-T cell treatments. The aging global population further contributes to market expansion. Additionally, ongoing clinical trials and approvals of novel agents are expected to boost market opportunities in the coming years. The anticipated launch of these emerging therapies for follicular lymphoma are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the follicular lymphoma market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. Scope of the Follicular Lymphoma Market Report Study Period: 2020-2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Follicular Lymphoma Companies: AbbVie (NYSE: ABBV), Genentech (subsidiary of Roche), Xynomic Pharma (OTC: XYNM), Regeneron (NASDAQ: REGN), Epizyme, Inc. (formerly NASDAQ: EPZM), ADC Therapeutics S.A (NYSE: ADCT), Kite Pharma (subsidiary of Gilead Sciences), Eli Lilly and Company (NYSE: LLY), Cephalon (acquired by Teva), Innovent Biologics (HKEX: 1801), Incyte Corporation (NASDAQ: INCY), Novartis (SWX: NOVN), MEI Pharma (NASDAQ: MEIP), AstraZeneca (LSE: AZN), BeiGene (NASDAQ: BGNE; HKEX: 6160), Millennium Pharma (subsidiary of Takeda), Roche (SWX: ROG), Gemin X (acquired by Cephalon), Pharmacyclics LLC. (formerly NASDAQ: PCYC), Xynomic Pharmaceuticals (OTC: XYNM), and others. Key Follicular Lymphoma Therapies: LUNSUMIO (mosunetuzumab), BRUKINSA (zanubrutinib), YESCARTA, MONJUVI (tafasitamab), AZD0486, Abexinostat, ME-401, Tisagenlecleucel, Parsaclisib (IBI376), Odronextamab, Mosunetuzumab, Abexinostat, Rituximab IV, Atezolizumab (MPDL3280A) [TECENTRIQ], Enzastaurin, Loncastuximab tesirine, Zanubrutinib, Bendamustine, Tazemetostat, ibrutinib, Obatoclax mesylate, Ibrutinib, IXAZOMIB, and others Follicular Lymphoma Therapeutic Assessment: Follicular Lymphoma current marketed and Follicular Lymphoma emerging therapies Follicular Lymphoma Market Dynamics: Follicular Lymphoma market drivers and Follicular Lymphoma market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Follicular Lymphoma Unmet Needs, KOL's views, Analyst's views, Follicular Lymphoma Market Access and Reimbursement Follicular Lymphoma Clinical Trials and FDA Approvals Table of Contents 1. Follicular Lymphoma Market Report Introduction 2. Executive Summary for Follicular Lymphoma 3. SWOT analysis of Follicular Lymphoma 4. Follicular Lymphoma Patient Share (%) Overview at a Glance 5. Follicular Lymphoma Market Overview at a Glance 6. Follicular Lymphoma Disease Background and Overview 7. Follicular Lymphoma Epidemiology and Patient Population 8. Country-Specific Patient Population of Follicular Lymphoma 9. Follicular Lymphoma Current Treatment and Medical Practices 10. Follicular Lymphoma Unmet Needs 11. Follicular Lymphoma Emerging Therapies 12. Follicular Lymphoma Market Outlook 13. Country-Wise Follicular Lymphoma Market Analysis (2020-2034) 14. Follicular Lymphoma Market Access and Reimbursement of Therapies 15. Follicular Lymphoma Market Drivers 16. Follicular Lymphoma Market Barriers 17. Follicular Lymphoma Appendix 18. Follicular Lymphoma Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
&w=3840&q=100)
Business Standard
24-06-2025
- Business
- Business Standard
Glenmark Pharma launches lung cancer treatment drug Tevimbra in India
Glenmark Pharmaceuticals on Tuesday said it has launched the lung cancer treatment drug Tevimbra in India, following the approval by the Central Drugs Standard Control Organisation. Tevimbra is developed by BeiGene (now BeOne Medicines), a global oncology leader. This launch marks Glenmark's first foray into immune-oncology in India and is a major milestone in expanding its innovative oncology portfolio, the company said in a regulatory filing. "At a time when the cancer burden is rising sharply, we are proud to enable oncologists and patients to access Tevimbra, a therapy with proven efficacy and safety outcomes, strong science, and meaningful impact," Glenmark Pharmaceuticals President and Business Head India Formulations Alok Malik said. Immuno-oncology offers a promising future for the treatment of various types of advanced cancers, which are difficult to treat, he said, adding that "Our foray in this area marks a significant inflection point in our journey to build a world-class oncology portfolio that is innovative, inclusive and at the same time life-changing for patients". Tevimbra is indicated for the treatment of first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) in combination with chemotherapy and second-line treatment of locally advanced or metastatic NSCLC and oesophagal squamous cell carcinoma (ESCC) as monotherapy, the company said. It is approved and marketed in multiple leading global markets, including the United States, European Union, Australia and China. (Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
Business Upturn
24-06-2025
- Business
- Business Upturn
Glenmark Pharmaceuticals launches TEVIMBRA in India for advanced lung and esophageal cancer treatment
By Aditya Bhagchandani Published on June 24, 2025, 09:50 IST Glenmark Pharmaceuticals has announced the launch of TEVIMBRA® (tislelizumab) in India, marking its entry into the immuno-oncology space. This anti-PD-1 monoclonal antibody, developed by global oncology firm BeiGene (now BeOne Medicines), is approved for the treatment of advanced non-small cell lung cancer (NSCLC) and esophageal squamous cell carcinoma (ESCC). The drug is designed to restore T-cell function and minimize off-target immune suppression, having shown strong efficacy and safety in global trials. Already approved in over 46 countries including the U.S. and EU, TEVIMBRA has been used in treating more than 1.5 million patients worldwide. Glenmark's President Alok Malik stated that the company is committed to transforming cancer care in India by making cutting-edge immunotherapies accessible. The launch comes at a time when cancer incidence in India is sharply rising, especially NSCLC and ESCC which dominate their respective cancer types in the country. This milestone aligns with Glenmark's broader ambition to build a globally benchmarked oncology portfolio, adding to its existing focus areas of respiratory and dermatology. Disclaimer: This content is for informational purposes only and not a substitute for professional medical advice. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
